Transcode Therapeutics, Inc. - RNAZ

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Aug 03, 2026 SCHEDULE 13D/A — 83.9% — View
Jul 28, 2026 SCHEDULE 13G Unleash Immuno Oncolytics, Inc. 9.94% 300,000 View
Jul 28, 2026 SCHEDULE 13G Elena Rosa Braci 6.17% 186,236 View
Jul 28, 2026 SCHEDULE 13G Daniel Eduardo Katzman 5.16% 155,611 View
Jul 27, 2026 SCHEDULE 13D/A — 83.9% — View
Jul 23, 2026 SCHEDULE 13D/A — 9.9% — View
Jul 17, 2026 SCHEDULE 13D/A — 9.99% — View
Apr 20, 2026 SCHEDULE 13G YA II PN, Ltd. 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G YA Global Investments II (U.S.), LP 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G Yorkville Advisors Global, LP 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G Yorkville Advisors Global II, LLC 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G YAII GP, LP 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G YAII GP II, LLC 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G Mark Angelo 9.9% 101,772 View
Apr 20, 2026 SCHEDULE 13G SC-Sigma Global Partners, LP 9.9% 101,772 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.